The difference observed between the release profiles of F1, F2, F3 and F4 was statistically significant (P < 0.05). Thus, PEO 303 was observed to be a suitable polymer for developing the sustained release matrices for aceclofenac. Formulations F2 (PEO N60K) and F4 (PEO 303) release the drug over a period of 12 h by swelling and subsequently eroding. 7 The similarity in the release profiles of commercial sustained release tablet and the developed formulations was compared by calculating the similarity factor (f2).8 The f2 values, when compared with Hifenac

SR, were observed to be 54.43, 62.72, 55.61 and 44.23 for formulations F5, F6, F7 & F8 respectively. The release showed less similarity when compared with Hifenac SR. Some amount of PEO 303 in the tablets was replaced with Polyox N60K at 10% (F9), 20% (F10) and 30% (F11) in formulation 5 FU F6 by keeping the total polymer percent at 28% to get the comparable release profile (higher similarity (f2) value). Selleck BIBW2992 The drug release was increased from the formulations in the order

of F9 < F10 < F11 (Fig. 4). Formulation, F10 showed higher similarity factor 77.68 when compared to F9 (68.23) and F11 (62.04). The mechanism of aceclofenac release was analyzed by using an empirical equation proposed by Ritger and Peppas.9 The release exponent “n”, was in the range of 0.513–0.795 for all the matrix tablets, indicating non-Fickian (anomalous) diffusion as the release mechanism. The time required for 50% of the drug to be released Oxygenase (T50 h), of the prepared formulations, increased as the PEO amount increased, in all the formulations ( Table

2). In the formulations F9, F10 and F11, the T50 value is decreased by increasing the Polyox N60K. This is the expected pattern in release profile because a part of high molecular Libraries weight PEO 7 × 106 was replaced with low molecular weight PEO 7 × 106. The T50% values of all the formulations tested were in the range of 9.25–17.5 h. The T50 value of formulation F10 (13.9 h) was very close to the T50 value of Hifenac SR (14.1 h), indicating that both exhibited the same in vitro performance. The drug release from the formulation F10 is fast at initial hours when compared to Hifenac SR ( Fig. 5) but the difference in drug release is not more than 5% at any time point. The similarity in release profiles is confirmed by the similarity factor of 77.68. The formulation F10 was optimized to test for in vivo bioavailability study along with Hifenac SR. The formulation F10 was containing the polymer at 28% to the total tablet weight and containing high molecular weight PEO 7 × 106 at 80% combining with low molecular weight 2 × 106 at 20% in the total polymer amount. The pharmacokinetic evaluation indicated that aceclofenac from formulation F10 and from Hifenac SR was released slowly and absorbed over long periods of time.